Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial

Fig. 4The alternative text for this image may have been generated using AI.

a Forest plot analysis of objective response rates (ORR) per patient subgroups in the main study cohort (n = 111). RTHYN, prior receipt of radiotherapy; SMKYN, prior or current smokers. The Kaplan–Meier curve for estimated PFS in the intention-to-treat population of phase II trial with (b) and without (c) baseline brain metastases who were treated with unecritinib. d The Kaplan Meier curve for estimated intracranial PFS. Vertical lines on the survival curve indicate the censoring of data

Back to article page